Royalty Pharma Commits $100M to Zealand's Rusfertide
RPRX sits 74% above its 52-week low of $34.081.
Summary
Royalty Pharma is putting $100 million into Zealand Pharma's rusfertide, a late-stage drug for polycythemia vera. This is a new royalty-style funding deal, not a rehash of prior news. The company has been active in expanding its royalty portfolio, and this adds a meaningful asset. The deal size is modest relative to Royalty Pharma's $34 billion market cap, but it signals continued deal flow. Watch for further details on the royalty rate and milestone structure.
At the time of this announcement, RPRX was trading at $59.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.1B. The 52-week trading range was $34.08 to $60.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.